Renowned Madagascar Scientist, Explorer and Mentor Named Winner of World's Leading Animal Conservation Award
NEW YORK, May 13, 2025 /CNW/ -- Officials from the Indianapolis Zoo announce Dr. Lily-Arison René de Roland, renowned scientist and biodiversity conservationist in Madagascar, as the 2025 Winner of the Indianapolis Prize.
Throughout his years of research and expeditions, René de Roland has discovered several new species, led the establishment of four national protected areas and developed community-focused conservation programs. Since 2004, he has been the National Director of The Peregrine Fund's Madagascar Program, where he oversees a team of 48 Malagasy conservationists working to conserve wildlife and landscapes in his homeland.
René de Roland is the tenth Winner of the Indianapolis Prize.
"Dr. René de Roland's community-based models and decades of research have not only alleviated human-wildlife conflicts—they have also helped to conserve Madagascar's unique and wonderful animals and ecosystems. He is dedicated, resourceful and a fierce advocate for Madagascar wildlife, and I'm proud to announce him as this year's Indianapolis Prize Winner," said Dr. Rob Shumaker, President and CEO of the Indianapolis Zoo.
René de Roland's contribution to the discovery of a variety of species is substantial, including the rediscovery of the Madagascar pochard, a rare duck thought to be extinct since the 1990s. He and his team rediscovered the species during a challenging expedition to a remote area of northern Madagascar in 2006. René de Roland has also contributed to the discovery of two previously undescribed lemur species in northern Madagascar. Due to his extensive impact on biodiversity conservation, scientists named a newly described wolf spider, Katableps lilyarisoni, after René de Roland in 2021. Most recently, during a 2022 expedition, René de Roland led a team to the rediscovery of the Dusky tetraka, a small songbird that had eluded ornithologists for 20 years.
"I am honored to receive this prestigious award from the Indianapolis Zoo," said René de Roland. "My work is inspired by my pride for my country's biodiversity and my love for its wonderful people."
René de Roland has led the creation of four national protected areas in Madagascar totaling over 1,500 square miles, including rainforests, dry forests, wetlands, mangroves and savannahs. These efforts not only preserve endemic Madagascar species under threat but also improve the lives of local people, with whom René de Roland works to manage these areas and sustainably leverage their resources.
Through his work, René de Roland has also helped to shape the next generation of Malagasy conservationists. His legacy extends to more than 100 students at local Madagascar universities, with his mentees earning 90 master's degrees and 16 doctoral degrees.
"The Peregrine Fund is tremendously proud of Lily, whose commitment to science, conservation and his community inspires us all," said Chris N. Parish, President and CEO of The Peregrine Fund. "We are beyond excited that the Indianapolis Prize is recognizing him for his research, mentorship and decades of work in the conservation profession."
René de Roland earned his master's degree, doctoral degree and professorship at the University of Antananarivo in Madagascar. He joined The Peregrine Fund as a student in 1992 to study Madagascar's imperiled raptors.
Established by the Indianapolis Zoo in 2004, the Indianapolis Prize recognizes and rewards the world's preeminent animal conservationists who have achieved major victories in advancing the sustainability of an animal species or group of species. Winners receive $250,000, which is the largest individual monetary award given in the animal conservation field.
René de Roland, the 2025 Indianapolis Prize DeHaan Finalists and the 2025 Indianapolis Prize Emerging Conservationist Award Winner will be celebrated at the Indianapolis Prize Gala on Sept. 27, 2025, presented by Cummins Inc., in downtown Indianapolis.
For additional media assets for the 2025 Indianapolis Prize, click here. To learn more about the previous Indianapolis Prize Winners, visit IndianapolisPrize.org.
About the Indianapolis Prize
The Indianapolis Prize recognizes and rewards conservationists who have achieved major victories in advancing the sustainability of an animal species or group of species. The Emerging Conservationist Award, a newly established accolade in 2023, is given to a conservationist aged 40 or younger. Since 2004, the Indianapolis Prize has awarded more than $7.5 million in unrestricted cash awards, advancing the work of conservation scientists through financial support and public awareness. The Indianapolis Prize is a conservation initiative of the Indianapolis Zoo.
Connect with the Prize on Facebook, X, Instagram and indianapolisprize.org.
View original content to download multimedia:https://www.prnewswire.com/news-releases/renowned-madagascar-scientist-explorer-and-mentor-named-winner-of-worlds-leading-animal-conservation-award-302451258.html
SOURCE Indianapolis Zoo
View original content to download multimedia: http://www.newswire.ca/en/releases/archive/May2025/13/c6098.html
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
a day ago
- Yahoo
GSK invests $300,000 to help launch the Pharmacy Innovation in Immunization Research Collaborative (PIIRC) at the University of Waterloo School of Pharmacy
PIIRC serves as a catalyst for innovation by supporting interdisciplinary research and real-world evidence generation focused on improving vaccine access, delivery and education. MISSISSAUGA, ON, June 6, 2025 /CNW/ - GSK is proud to announce a $300,000 investment in the Pharmacy Innovation in Immunization Research Collaborative (PIIRC), a new national initiative led by the School of Pharmacy at the University of Waterloo. This groundbreaking initiative reflects a shared commitment to expanding the role of pharmacy in Canada's immunization landscape and improving equitable access to vaccines across the country. Immunization has never been more critical. The COVID-19 pandemic underscored the life-saving power of vaccines and demonstrated the essential role that pharmacists and pharmacies play in public health. Pharmacy teams have administered more than 20 million COVID-19 vaccines in Canada alone. Yet, there remains untapped potential to leverage the country's 11,000+ pharmacies as accessible, community-based hubs for broader immunization services. PIIRC aims to close that gap. Launched by the largest clinical pharmacy practice research group in Canada, PIIRC serves as a catalyst for innovation by supporting interdisciplinary research and real-world evidence generation focused on improving vaccine access, delivery and education. The initiative brings together researchers from the University of Waterloo, national and international collaborators, policymakers and stakeholders across healthcare and industry to advance pharmacy-based immunization strategies. "As a global leader in vaccines, we believe in harnessing science and partnerships to tackle the world's most pressing health challenges," said Michelle Horn, Country Medical Director, GSK Canada. "Through our founding partnership with PIIRC, we are investing not only in research, but in the future of vaccine delivery in Canada—one that is more accessible, equitable, and community-centred." Transforming Immunization Through Pharmacy Innovation The objective of PIIRC is to re-imagine the role of pharmacy in immunization—from vaccine administration to health education, monitoring, and system design. Areas of research will include: Expanding the role of pharmacists and pharmacy technicians as vaccine educators, facilitators, and immunizers Overcoming barriers to access, especially among rural residents, older adults, immunocompromised individuals, and other underserved populations Leveraging digital health tools and technology to support clinical decision-making and personalized outreach Countering vaccine misinformation through evidence-based communication strategies and resources for healthcare providers Conducting economic analyses to examine the cost-effectiveness and public health value of pharmacy-based vaccine services Implementing science methodologies to ensure successful and scalable solutions across regions and populations This work will be supported by the School's extensive expertise in pharmacy practice research, health systems design, health economics, public policy, behavioural science, and communication strategies. "As a leader in clinical pharmacy practice research and community pharmacy innovation, the University of Waterloo's School of Pharmacy continues to push boundaries," said Andrea Edginton, Hallman Director, School of Pharmacy at the University of Waterloo. "PIIRC is a natural evolution of our work in immunization, and GSK's partnership will accelerate breakthroughs that improve public health both in Canada and globally." Impact Beyond the Lab In addition to funding innovative research, GSK's investment will also: Provide funding to support new interdisciplinary projects with direct policy and practice implications Train the next generation of immunization researchers, including PharmD students, graduate students and postdoctoral fellows Facilitate enhanced access to real-world pharmacy data to monitor vaccine uptake and identify areas for intervention Establish a network of community pharmacies engaged in research, data collection and pilot projects Enable regular knowledge translation activities to ensure research is informed by and disseminated to industry, government and community stakeholders Support the creation of an Advisory Board that includes voices from pharmaceutical and insurance companies, regulators, pharmacy associations and the public Strategic Alignment with Public Health and Policy This investment directly supports the Ontario Life Sciences Strategy by demonstrating private sector leadership in supporting community-based immunization services. By investing in evidence that shows how pharmacy can help achieve broader public health goals—including for future vaccine program rollouts such as RSV—GSK is playing a critical role in advancing both healthcare outcomes and policy development. "Our support for PIIRC is not just about generating data; it's about making a meaningful contribution to the future of healthcare," added Michelle Horn, Country Medical Director, GSK Canada. "We're proud to stand alongside the University of Waterloo School of Pharmacy in driving innovative, patient-centred immunization strategies that reflect our mission to get ahead of disease together and our commitment to doing what's right for communities and for public health." Why Waterloo and Why Now? The University of Waterloo's collaborative ethos, track record of external partnerships and commitment to impact make it an ideal home for PIIRC. The University creates substantial opportunities for high-impact partnerships that bridge the gap between research and application. PIIRC helps shape policy and guides decision-making with timely, actionable evidence that reflects the realities of patients, pharmacists and public health professionals. GSK's early and decisive investment solidifies its reputation as a forward-thinking leader in the pharmacy space and a partner of choice in advancing vaccine innovation. About the University of Waterloo School of PharmacyThe School of Pharmacy at the University of Waterloo is home to Canada's largest clinical pharmacy practice research group and is at the forefront of pharmacy innovation. Through interdisciplinary research and industry collaboration, the School is advancing pharmacy's role in improving health systems and patient outcomes. About GSK GSK is a global biopharma company with a purpose to unite science, technology and talent to get ahead of disease together. Find out more at Cautionary statement regarding forward-looking statements GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described in the "Risk Factors" section in GSK's Annual Report on Form 20-F for 2024, and GSK's Q1 Results for 2025. SOURCE GlaxoSmithKline Inc. View original content to download multimedia: Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 days ago
- Yahoo
ZEISS CLARUS 700 Receives NMPA Approval in China
ZEISS Medical Technology expands retinal insights for ophthalmologists with ultra-widefield, high-resolution imaging capabilities JENA, Germany and SHANGHAI, June 5, 2025 /CNW/ -- ZEISS Medical Technology announced today that the CLARUS® 700 from ZEISS has received National Medical Products Administration (NMPA) approval in China, offering advanced retinal diagnostic capabilities with ultra-widefield, high-resolution images in True Color and unsurpassed quality. The fundus imaging device with Fluorescein Angiography helps eye care specialists in China unlock the full potential of their clinic's retina workflow to support improved patient vision preservation. "ZEISS CLARUS 700 represents a major step forward in retinal imaging," emphasizes Anuj Kalra, Head of Chronic Disease Management at ZEISS Medical Technology. "By seamlessly integrating ultra-widefield Fluorescein Angiography (FA) imaging with true-color reproduction, this system delivers unprecedented clarity for comprehensive visualization from the macular region to the extreme retinal periphery, enhancing efficiency and supporting precise decision-making within the ZEISS Retina Workflow." "Integrating ultra-widefield imaging, unsurpassed clarity, and AI-enhanced capture, the CLARUS 700 redefines fundus angiography benchmarks. It will provide unparalleled diagnostic precision for Chinese doctors and unprecedented comfort for their patients," says Maxwell Liu, Head of Sales & Services at ZEISS Medical Technology China. Ultra-widefield fluorescein angiography serves as a highly valuable examination tool for assessing nonperfused retinal areas. The ZEISS CLARUS 700 HD ultra-widefield fundus imaging camera is an advanced retinal imaging system that provides True Color, high-resolution images. It captures 133°1 in a single image and up to 267° with multiple captures, offering detailed views of the retina. Equipped with both fluorescein angiography and live infrared imaging capabilities, the CLARUS 700 aids in diagnosing and monitoring retinal diseases2. Furthermore, the fundus imaging camera offers innovative technology features including PrecisionFocus for quickly seeing details in the regions of interest, QuickCompare to compare pathology changes observed in past patient visits, and AutoBright so ophthalmologists can spend more time analyzing images and less time adjusting them. More information about the CLARUS® 700 from ZEISS can be found here. 1 CLARUS 700#white-paper2 Xiao, Y., Dan, H., Du, X. et al. Assessment of early diabetic retinopathy severity using ultra-widefield Clarus versus conventional five-field and ultra-widefield Optos fundus imaging. Sci Rep 13, 17131 (2023). Not all products, services or offers are approved or offered in every market and approved labeling and instructions may vary from one country to another. For country-specific product information, see the appropriate country website. Product specifications are subject to change in design and scope of delivery as a result of ongoing technical development. The statements of the healthcare professionals reflect only their personal opinions and experiences and do not necessarily reflect the opinion of any institution that they are affiliated with. The healthcare professionals alone are responsible for the content of their experience reported and any potential resulting infringements. Carl Zeiss Meditec AG and its affiliates to not have clinical evidence supporting the opinions and statements of the health care professionals nor accept any responsibility or liability of the healthcare professionals' content. The healthcare professionals have a contractual or other financial relationship with Carl Zeiss Meditec AG and its affiliates and have received financial support. Contact for investorsSebastian FrericksDirector Investor RelationsCarl Zeiss Meditec AGPhone: +49 3641 220 116Mail: Contact for the pressFrank SmithHead of Global Communications OphthalmologyCarl Zeiss Meditec +49 3641 220 331Mail: Brief Profile Carl Zeiss Meditec AG (ISIN: DE0005313704), which is listed on the MDAX and TecDAX of the German stock exchange, is one of the world's leading medical technology companies. The Company supplies innovative technologies and application-oriented solutions designed to help doctors improve the quality of life of their patients. The Company offers complete solutions, including implants and consumables, to diagnose and treat eye diseases. The Company creates innovative visualization solutions in the field of microsurgery. With 5,730 employees worldwide, the Group generated revenue of €2,066.1m in fiscal year 2023/24 (to 30 September). The Group's head office is located in Jena, Germany, and it has subsidiaries in Germany and abroad; more than 50 percent of its employees are based in the USA, Japan, Spain and France. The Center for Application and Research (CARIn) in Bangalore, India and the Carl Zeiss Innovations Center for Research and Development in Shanghai, China, strengthen the Company's presence in these rapidly developing economies. Around 39 percent of Carl Zeiss Meditec AG's shares are in free float. Approx. 59 percent are held by Carl Zeiss AG, one of the world's leading groups in the optical and optoelectronic industries. For further information visit: View original content to download multimedia: SOURCE Carl Zeiss Meditec AG View original content to download multimedia: Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 days ago
- Yahoo
ZEISS CLARUS 700 Receives NMPA Approval in China
ZEISS Medical Technology expands retinal insights for ophthalmologists with ultra-widefield, high-resolution imaging capabilities JENA, Germany and SHANGHAI, June 5, 2025 /CNW/ -- ZEISS Medical Technology announced today that the CLARUS® 700 from ZEISS has received National Medical Products Administration (NMPA) approval in China, offering advanced retinal diagnostic capabilities with ultra-widefield, high-resolution images in True Color and unsurpassed quality. The fundus imaging device with Fluorescein Angiography helps eye care specialists in China unlock the full potential of their clinic's retina workflow to support improved patient vision preservation. "ZEISS CLARUS 700 represents a major step forward in retinal imaging," emphasizes Anuj Kalra, Head of Chronic Disease Management at ZEISS Medical Technology. "By seamlessly integrating ultra-widefield Fluorescein Angiography (FA) imaging with true-color reproduction, this system delivers unprecedented clarity for comprehensive visualization from the macular region to the extreme retinal periphery, enhancing efficiency and supporting precise decision-making within the ZEISS Retina Workflow." "Integrating ultra-widefield imaging, unsurpassed clarity, and AI-enhanced capture, the CLARUS 700 redefines fundus angiography benchmarks. It will provide unparalleled diagnostic precision for Chinese doctors and unprecedented comfort for their patients," says Maxwell Liu, Head of Sales & Services at ZEISS Medical Technology China. Ultra-widefield fluorescein angiography serves as a highly valuable examination tool for assessing nonperfused retinal areas. The ZEISS CLARUS 700 HD ultra-widefield fundus imaging camera is an advanced retinal imaging system that provides True Color, high-resolution images. It captures 133°1 in a single image and up to 267° with multiple captures, offering detailed views of the retina. Equipped with both fluorescein angiography and live infrared imaging capabilities, the CLARUS 700 aids in diagnosing and monitoring retinal diseases2. Furthermore, the fundus imaging camera offers innovative technology features including PrecisionFocus for quickly seeing details in the regions of interest, QuickCompare to compare pathology changes observed in past patient visits, and AutoBright so ophthalmologists can spend more time analyzing images and less time adjusting them. More information about the CLARUS® 700 from ZEISS can be found here. 1 CLARUS 700#white-paper2 Xiao, Y., Dan, H., Du, X. et al. Assessment of early diabetic retinopathy severity using ultra-widefield Clarus versus conventional five-field and ultra-widefield Optos fundus imaging. Sci Rep 13, 17131 (2023). Not all products, services or offers are approved or offered in every market and approved labeling and instructions may vary from one country to another. For country-specific product information, see the appropriate country website. Product specifications are subject to change in design and scope of delivery as a result of ongoing technical development. The statements of the healthcare professionals reflect only their personal opinions and experiences and do not necessarily reflect the opinion of any institution that they are affiliated with. The healthcare professionals alone are responsible for the content of their experience reported and any potential resulting infringements. Carl Zeiss Meditec AG and its affiliates to not have clinical evidence supporting the opinions and statements of the health care professionals nor accept any responsibility or liability of the healthcare professionals' content. The healthcare professionals have a contractual or other financial relationship with Carl Zeiss Meditec AG and its affiliates and have received financial support. Contact for investorsSebastian FrericksDirector Investor RelationsCarl Zeiss Meditec AGPhone: +49 3641 220 116Mail: Contact for the pressFrank SmithHead of Global Communications OphthalmologyCarl Zeiss Meditec +49 3641 220 331Mail: Brief Profile Carl Zeiss Meditec AG (ISIN: DE0005313704), which is listed on the MDAX and TecDAX of the German stock exchange, is one of the world's leading medical technology companies. The Company supplies innovative technologies and application-oriented solutions designed to help doctors improve the quality of life of their patients. The Company offers complete solutions, including implants and consumables, to diagnose and treat eye diseases. The Company creates innovative visualization solutions in the field of microsurgery. With 5,730 employees worldwide, the Group generated revenue of €2,066.1m in fiscal year 2023/24 (to 30 September). The Group's head office is located in Jena, Germany, and it has subsidiaries in Germany and abroad; more than 50 percent of its employees are based in the USA, Japan, Spain and France. The Center for Application and Research (CARIn) in Bangalore, India and the Carl Zeiss Innovations Center for Research and Development in Shanghai, China, strengthen the Company's presence in these rapidly developing economies. Around 39 percent of Carl Zeiss Meditec AG's shares are in free float. Approx. 59 percent are held by Carl Zeiss AG, one of the world's leading groups in the optical and optoelectronic industries. For further information visit: View original content to download multimedia: SOURCE Carl Zeiss Meditec AG View original content to download multimedia:
